MEN 1309

Drug Profile

MEN 1309

Alternative Names: MEN-1309; OBT 076

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioTherapeutics
  • Developer Menarini; Oxford BioTherapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action DEC-205 receptor modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours
  • Preclinical Bladder cancer; Breast cancer; Pancreatic cancer

Most Recent Events

  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Belgium (unspecified route)
  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Italy (unspecified route)
  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top